$MTLK
METALINK LTD

2022 Q4 Form 20-F Financial Statement

#000109690623000926 Filed on April 27, 2023

View on sec.gov

Income Statement

Concept 2022 Q4 2022 2021 Q4
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses
YoY Change
Operating Profit -$41.00K
YoY Change -4.65%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income $15.00K
YoY Change -137.5%
Income Tax $0.00
% Of Pretax Income 0.0%
Net Earnings $15.00K
YoY Change -137.5%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share
COMMON SHARES
Basic Shares Outstanding 1.256M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q4 2022 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $18.00K $13.00K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets
YoY Change
TOTAL ASSETS
Total Short-Term Assets
Total Long-Term Assets
Total Assets $1.909M $1.888M
YoY Change 1.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $168.0K $162.0K
YoY Change 3.7%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $168.0K $162.0K
Total Long-Term Liabilities
Total Liabilities
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$145.1M -$145.1M
YoY Change -0.01%
Common Stock $790.0K $790.0K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost) $12.04M $12.04M
YoY Change 0.0%
Treasury Stock Shares 1.525M shares 1.525M shares
Shareholders Equity $1.741M $1.726M
YoY Change
Total Liabilities & Shareholders Equity $1.909M $1.888M
YoY Change 1.11%

Cashflow Statement

Concept 2022 Q4 2022 2021 Q4
OPERATING ACTIVITIES
Net Income $15.00K
YoY Change -137.5%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$15.00K
YoY Change -62.5%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $20.00K
YoY Change -108.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities -$15.00K
Cash From Investing Activities $20.00K
Cash From Financing Activities
Net Change In Cash $5.000K
YoY Change -101.74%
FREE CASH FLOW
Cash From Operating Activities -$15.00K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Auditor Location
AuditorLocation
Jerusalem, Israel
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18000 usd
CY2022 dei Document Type
DocumentType
20-F
CY2022 dei Document Registration Statement
DocumentRegistrationStatement
false
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Document Shell Company Report
DocumentShellCompanyReport
false
CY2022 dei Entity File Number
EntityFileNumber
000-30394
CY2022 dei Entity Registrant Name
EntityRegistrantName
Metalink Ltd.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
L3
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
Haaliya 24
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Beit-Yitzhak
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
4292000
CY2022 dei Entity Address Country
EntityAddressCountry
IL
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1255640 shares
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Document Accounting Standard
DocumentAccountingStandard
U.S. GAAP
CY2022 dei Entity Shell Company
EntityShellCompany
true
CY2022 dei Auditor Firm
AuditorFirmId
2015
CY2022 dei Auditor Name
AuditorName
Barzily & Co
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13000 usd
CY2022Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
1891000 usd
CY2021Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
1875000 usd
CY2022Q4 us-gaap Assets
Assets
1909000 usd
CY2021Q4 us-gaap Assets
Assets
1888000 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
168000 usd
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
162000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
168000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
162000 usd
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
5000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
5000000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2780707 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2780707 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1255640 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1255640 shares
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
790000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
790000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
158111000 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
158111000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-145122000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-145137000 usd
CY2022Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
1525067 shares
CY2021Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
1525067 shares
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
12038000 usd
CY2021Q4 us-gaap Treasury Stock Value
TreasuryStockValue
12038000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1741000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
1726000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1909000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1888000 usd
CY2022 us-gaap Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
10000 usd
CY2021 us-gaap Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
7000 usd
CY2020 us-gaap Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
8000 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
41000 usd
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
43000 usd
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
48000 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-41000 usd
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-43000 usd
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-48000 usd
CY2022 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
56000 usd
CY2021 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
3000 usd
CY2020 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
25000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
15000 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-40000 usd
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-23000 usd
CY2022 fil Basic And Diluted Profit Loss
BasicAndDilutedProfitLoss
0.012
CY2021 fil Basic And Diluted Profit Loss
BasicAndDilutedProfitLoss
-0.032
CY2020 fil Basic And Diluted Profit Loss
BasicAndDilutedProfitLoss
-0.018
CY2022 fil Weighted Average Number Of Share Outstanding Basic And Diluted1
WeightedAverageNumberOfShareOutstandingBasicAndDiluted1
1255640 shares
CY2021 fil Weighted Average Number Of Share Outstanding Basic And Diluted1
WeightedAverageNumberOfShareOutstandingBasicAndDiluted1
1255640 shares
CY2020 fil Weighted Average Number Of Share Outstanding Basic And Diluted1
WeightedAverageNumberOfShareOutstandingBasicAndDiluted1
1255640 shares
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
1789000 usd
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-23000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
1766000 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-40000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
1726000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
15000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1741000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
15000 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-40000 usd
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-23000 usd
CY2022 fil Deposit Revaluation
DepositRevaluation
-36000 usd
CY2021 fil Deposit Revaluation
DepositRevaluation
-3000 usd
CY2020 fil Deposit Revaluation
DepositRevaluation
-5000 usd
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
6000 usd
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3000 usd
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
17000 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15000 usd
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-40000 usd
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11000 usd
CY2022 fil Payments For Deposit
PaymentsForDeposit
-20000 usd
CY2021 fil Payments For Deposit
PaymentsForDeposit
248000 usd
CY2020 fil Payments For Deposit
PaymentsForDeposit
-300000 usd
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
20000 usd
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-248000 usd
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
300000 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
5000 usd
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-288000 usd
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
289000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
301000 usd
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
301000 usd
CY2022 fil Interest Obtained During The Year
InterestObtainedDuringTheYear
8000 usd
CY2021 fil Interest Obtained During The Year
InterestObtainedDuringTheYear
6000 usd
CY2020 fil Interest Obtained During The Year
InterestObtainedDuringTheYear
49000 usd
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
1891000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13000 usd
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
1875000 usd
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="font:10pt Times New Roman;margin:0;margin-left:85.05pt"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:-28.35pt"><b>A.</b></kbd><span style="border-bottom:1px solid #000000"><b>Use of Estimates in Preparation of Financial Statements</b></span> </p> <p style="font:10pt Times New Roman;margin:0;margin-left:85.05pt;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;margin-left:85.05pt;color:#000000">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reported period. Actual results could differ from those estimates.</p>
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font:10pt Times New Roman;margin:0;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;margin-left:85.05pt"><kbd style="position:absolute;font:10pt Times New Roman;margin-left:-28.35pt"><b>E.</b></kbd><span style="border-bottom:1px solid #000000"><b>Concentrations of Credit Risk</b></span> </p> <p style="font:10pt Times New Roman;margin:0;margin-left:85.5pt;color:#000000"> </p> <p style="font:10pt Times New Roman;margin:0;margin-left:85.5pt;color:#000000">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and bank deposits.</p> <p style="font:10pt Times New Roman;margin:0;margin-left:85.5pt"> </p> <p style="font:10pt Times New Roman;margin:0;margin-left:85.05pt">As of December 31, 2022, the Company had cash and cash equivalents that totaled to $18 and short-term deposits totaling to $1,891, all of which were deposited in a major Israeli financial institution. As of December 31, 2021, the Company had cash and cash equivalents that totaled to $13 and short-term deposits totaling to $1,875, all of which were deposited in a major Israeli financial institution. The risk to the Company is solely dependent upon daily bank balances and the respective strength of the financial institution. The Company has not incurred any losses on these accounts. Management believes that the financial institutions holding the Company's cash and cash equivalents and its deposits are financially sound.</p> <p style="font:10pt Times New Roman;margin:0;color:#000000"> </p>
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18000 usd
CY2022 us-gaap Payments For Royalties
PaymentsForRoyalties
268000 usd
CY2022Q4 fil Provision For Contingent Liabilities
ProvisionForContingentLiabilities
128000 usd
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
0 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
112500 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.50
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
112500 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.50
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
0 shares
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
112500 shares
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
1.50
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
0 shares
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
0 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
0 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
112500 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.50
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
CY2021Q4 us-gaap Share Price
SharePrice
1.05
CY2020Q4 us-gaap Share Price
SharePrice
0.43
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
15000 usd
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-40000 usd
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-23000 usd
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.230 pure
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.230 pure
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.230 pure
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
3400 usd
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-9200 usd
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-5300 usd
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-3400 usd
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
9200 usd
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
5300 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2020Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
226000 usd
CY2021Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
233000 usd
CY2022Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
206000 usd
CY2022Q4 fil Provision For Legal Claims
ProvisionForLegalClaims
128000 usd
CY2021Q4 fil Provision For Legal Claims
ProvisionForLegalClaims
128000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
40000 usd
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
34000 usd
CY2022Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
168000 usd
CY2021Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
162000 usd
CY2022 us-gaap Investment Income Net
InvestmentIncomeNet
56000 usd
CY2021 us-gaap Investment Income Net
InvestmentIncomeNet
6000 usd
CY2020 us-gaap Investment Income Net
InvestmentIncomeNet
49000 usd
CY2022 fil Income Expense From Revaluation Of Deposits
IncomeExpenseFromRevaluationOfDeposits
0 usd
CY2021 fil Income Expense From Revaluation Of Deposits
IncomeExpenseFromRevaluationOfDeposits
-3000 usd
CY2020 fil Income Expense From Revaluation Of Deposits
IncomeExpenseFromRevaluationOfDeposits
-24000 usd
CY2022 fil Financial Income
FinancialIncome
56000 usd
CY2021 fil Financial Income
FinancialIncome
3000 usd
CY2020 fil Financial Income
FinancialIncome
25000 usd
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
112500 shares
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
112500 shares

Files In Submission

Name View Source Status
0001096906-23-000926-index-headers.html Edgar Link pending
0001096906-23-000926-index.html Edgar Link pending
0001096906-23-000926.txt Edgar Link pending
0001096906-23-000926-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mtlk-20221231.htm Edgar Link pending
mtlk-20221231.xsd Edgar Link pending
mtlk_ex12.htm Edgar Link pending
mtlk_ex13.htm Edgar Link pending
mtlk_ex15.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
mtlk-20221231_cal.xml Edgar Link unprocessable
mtlk-20221231_lab.xml Edgar Link unprocessable
mtlk-20221231_def.xml Edgar Link unprocessable
mtlk-20221231_pre.xml Edgar Link unprocessable
mtlk-20221231_htm.xml Edgar Link completed
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending